John Newman

In a report published Wednesday, Canaccord Genuity analyst John Newman assumed coverage on NPS Pharmaceuticals (NASDAQ: NPSP) with a Buy rating and $42.00 price target. In the report, Canaccord Genuity noted, “We recommend buying NPSP on recent market weakness based on its three high-priced orphan...

In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on Medivation (NASDAQ: MDVN) with a Hold rating and $60.00 price target. In the report, Canaccord Genuity noted, “We are initiating coverage on Medivation with a HOLD rating and $60 price target. We see 3Q14...

In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on Lpath (NASDAQ: LPTN) with a Buy rating and $17.00 price target. In the report, Canaccord Genuity noted, “We are initiating coverage of Lpath with a BUY rating and $17 price target. Lpath's iSONEP could be...

In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on ImmunoGen (NASDAQ: IMGN) with a Buy rating and $20.00 price target. In the report, Canaccord Genuity noted, “We are initiating coverage of ImmunoGen with a BUY rating and $20 price target. We expect...

On June 28th Warner Chilcott (NASDAQ:WRCX) announced it had received a Paragraph IV certification from Par Pharmaceuticals challenging Warner Chilcott's 400mg dose of Asacol. This is the second filing, after Roxane Laboratories. Oppenheimer analysts John Newman and Christopher Holterhoff do not see...

Oppenheimer analysts John Newman and Christopher Holterhoff maintained their Outperform rating for shares of Questcor Pharmaceuticals Inc (Nasdaq: QCOR), with a price target of $14 per share. The analysts said that although they expect a positive decision from the FDA for the use of Questcor...

Oppenheimer & Co. analysts John Newman and Christopher Holterhoff maintained their Outperform rating for shares of Eurand N.V. (Nasdaq: EURX), with a price target of $12 per share. The analysts increased their estimates for 2010 through 2012 due to lower estimated operating expenses. They said...

Oppenheimer analysts John Newman and Christopher Holterhoff maintained their Outperform rating and price target of $40 for shares of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP). The analysts said that they expect an FDA decision on XIFAXAN in HE by March 24 2010, with a launch date by late May and...